Menlo Park, CA, United States of America

Joseph K Belanoff

This inventor holds 41 USPTO granted patents and 17 published patent applications, plus 13 CIPO patents and 8 EPO patents, primarily in Glucocorticoid Therapy. Top assignees: Corcept Therapeutics Incorporated, Leland Stanford Junior University. Active years: 2000-2026.

USPTO Granted Patents = 41 (Patent Applications = 17)

% Patents Active = 100.0

CIPO Patents = 13 (Patent Applications = 2)

EPO Patents = 8 (Patent Applications = 12)

Average Co-Inventor Count = 1.6

ph-index = 10

Forward Citations = 260(Granted Patents)

Location History:

Cupertino, CA (US) (2000 - 2002)
Woodside, CA (US) (2002 - 2021)
Menlo Park, CA (US) (2019 - 2024)

Company Filing History:

38 out of 138

Corcept Therapeutics Incorporated

patents

3 out of 5,501

Leland Stanford Junior University

patents

Years Active: 2000-2026

Loading Chart...

Areas of Expertise:

Glucocorticoid Receptor Antagonists

Cushing's Syndrome

Fatty Liver Disease

Psychosis Treatment

Adrenal Insufficiency

Migraine Treatment

Antipsychotic-Induced Weight Gain

Muscular Dystrophy

Stress Disorders

Mental Disorders

Neurological Damage Prevention

Delirium Treatment

41 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12691127 - Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency (2026-07-28),

2. 12625150 - Treatment of, and differential diagnosis between, ACTH-dependent Cushing's syndrome and ACTH-independent Cushing's syndrome (2026-05-12),

3. 12616698 - Methods for reducing liver fat and for treating fatty liver disorders (2026-05-05),

4. 12226417 - Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists (2025-02-18),

5. 12109272 - Intermittent dosing of glucocorticoid receptor modulators for the treatment of ovarian and other cancers (2024-10-08),

6. 12097210 - Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors (2024-09-24),

7. 11969435 - Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors (2024-04-30),

8. 11903945 - Methods of treating antipsychotic-induced weight gain with miricorilant (2024-02-20),

9. 11890289 - Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency (2024-02-06),

10. 11590135 - Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists (2023-02-28),

11. 11268145 - Methods for treating Cushing's syndrome (2022-03-08),

12. 11202784 - Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency (2021-12-21),

13. 11173165 - Optimizing mifepristone levels for Cushing's patients (2021-11-16),

14. 11103514 - Treatment of muscular dystrophy (2021-08-31),

15. 10881660 - Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists (2021-01-05),

Title: **The Impact of Joseph K. Belanoff in Medical Innovations**

Introduction

Joseph K. Belanoff, based in Menlo Park, CA, is an influential inventor in the field of medical science, holding a significant portfolio of 38 patents. His work primarily focuses on innovative treatments for complex diseases, showcasing a passion for improving patient outcomes through groundbreaking medical solutions.

Latest Patents

Belanoff's latest patents include pioneering methods for treating fatty liver disease and various forms of cancer. One notable patent addresses treatment for fatty liver disease using glucocorticoid and mineralocorticoid receptor antagonists, specifically employing a class of pyrimidinedione cyclohexyl compounds. Another significant invention revolves around intermittent dosing of glucocorticoid receptor modulators for treating ovarian and other cancers. This method highlights the advantages of administering glucocorticoid receptor modulators, such as relacorilant, in conjunction with chemotherapy agents like bevacizumab, demonstrating improved survival and response rates for patients undergoing these treatments.

Career Highlights

Throughout his career, Joseph K. Belanoff has made considerable contributions to the medical field while working with prominent organizations, including Corcept Therapeutics Incorporated and Leland Stanford Junior University. His role in these organizations has been pivotal in advancing innovative therapies that address critical health issues.

Collaborations

Belanoff's collaborations with esteemed professionals such as Alan F. Schatzberg and Hazel Joan Hunt have further enriched his contributions to medical science. These partnerships have played an essential role in developing effective treatment methods and enhancing research outcomes in the field.

Conclusion

Joseph K. Belanoff’s work exemplifies the impact of innovation in medicine. His extensive patent portfolio and collaborations underscore his commitment to advancing healthcare solutions for diseases that affect millions. With continuous research and dedicated efforts, Belanoff remains a notable figure in the realm of medical inventions and innovations.